Beta Bionics (NASDAQ:BBNX) Upgraded at Barclays

Barclays upgraded shares of Beta Bionics (NASDAQ:BBNX) to a strong-buy rating in a research report released on Tuesday morning,Zacks reports.

A number of other research analysts have also recently issued reports on the company. Wells Fargo & Company began coverage on Beta Bionics in a research report on Wednesday, September 23rd. They issued an “overweight” rating and a $28.00 target price on the stock. Truist Financial raised their price target on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. Leerink Partners lifted their price target on shares of Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a report on Monday, September 14th. Wall Street Zen upgraded shares of Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. Finally, Bank of America increased their price objective on shares of Beta Bionics from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Tuesday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.50.

Beta Bionics Stock Performance

Shares of BBNX stock opened at $17.43 on Tuesday. The stock’s fifty day moving average price is $18.66 and its two-hundred day moving average price is $14.96. The company has a market cap of $784.18 million, a PE ratio of -10.56 and a beta of 3.39. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million during the quarter. On average, equities analysts predict that Beta Bionics will post -2.02 EPS for the current fiscal year.

Insider Transactions at Beta Bionics

In other news, insider Mark Hopman sold 36,870 shares of the business’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20. Following the sale, the insider directly owned 87,157 shares in the company, valued at approximately $1,608,918.22. The trade was a 29.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen Feider sold 6,675 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at $3,045,713.58. This represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 97,697 shares of company stock valued at $1,907,034. 5.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently added to or reduced their stakes in BBNX. Caitong International Asset Management Co. Ltd lifted its stake in shares of Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares during the period. Legal & General Group Plc bought a new stake in Beta Bionics in the second quarter valued at approximately $62,000. The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics during the 2nd quarter valued at approximately $172,000. Values First Advisors Inc. increased its position in Beta Bionics by 35.1% during the 1st quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock valued at $476,000 after purchasing an additional 12,360 shares during the period. Finally, Ieq Capital LLC bought a new position in Beta Bionics during the 2nd quarter worth approximately $229,000.

Beta Bionics News Roundup

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Barclays upgrade: Barclays raised Beta Bionics to “strong-buy,” potentially supporting investor confidence and demand for the shares. Barclays upgrades Beta Bionics
• Positive Sentiment: Mint clearance and valuation revisions: A report said the company’s fair-value estimate increased following Mint clearance and changes to analyst price targets, suggesting some analysts see improved commercial or regulatory prospects. Beta Bionics fair value rises after Mint clearance
• Neutral Sentiment: Legal deadline: Multiple law firms are soliciting investors who purchased BBNX shares between July 30, 2025, and February 24, 2026, ahead of a November 3, 2026 lead-plaintiff deadline. These notices largely repeat the same underlying lawsuit rather than represent separate new cases. Rosen Beta Bionics class action notice
• Negative Sentiment: Securities litigation and FDA concerns: Beta Bionics faces a securities class action alleging that management understated the significance of an FDA Form 483 and concerns involving its automated insulin-delivery system, iLet. Reports allege more than 18,000 unreported complaints and say subsequent FDA disclosures contributed to a sharp prior decline in the shares. The litigation creates reputational, regulatory and potential financial risks. Beta Bionics securities class action alert

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing and commercializing automated insulin delivery systems for people with insulin-requiring diabetes. Its lead product is the iLet Bionic Pancreas, an insulin pump system designed to automate much of the insulin-dosing process and reduce the daily burden associated with diabetes management.

The iLet Bionic Pancreas uses continuous glucose monitoring data and the company’s dosing algorithms to deliver insulin. Unlike conventional insulin pumps that generally require users to calculate meal doses, the system is designed to simplify mealtime dosing by using a person’s body weight and meal announcements as key inputs.